Abstract
In addition to their metabolic function of storing triglycerides and releasing free fatty acids upon hormonal stimulation, adipocytes are now recognized as behaving as secretory cells. During the past 10 yr, an increasing number of peptidic and nonpeptidic compounds have been demonstrated to be secreted by adipocytes (1). Most of these compounds are thought to exert primarily, and in an autocrine/paracrine manner, local effects that modulate adipose cell hypertrophy and/or hyperplasia of adipose tissue (AT). This is essentially the case for short-living molecules, such as the prostanoid, prostacyclin (PGI2), which is discussed in this chapter. Some of these secreted factors, like leptin (see Chapter 26), allow communication with other peripheral tissues and the central nervous system, giving to the adipocyte the status of an endocrine cell. In addition, some of these factors may contribute to the development of morbid complications of obesity, i.e., cardiovascular diseases, hypertension, insulin-resistance, diabetes, and cancer (2).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Négrel, R. (1999) Paracrine/autocrine signals and adipogenesis, in Progress in Obesity Research (Guy-Grand, B. and Ailhaud, G., eds.), John Libbey, London, UK, pp. 55–63.
Arner, P. (1999) Physiopathology of visceral adipose tissue, in Progress in Obesity Research (Guy-Grand, B. and Ailhaud, G., eds.), John Libbey, London, UK, pp. 567–572.
Lee., M. A., Bohm, M., Paul, M., and Ganten, D. (1993) Tissue renin-angiotensinogen systems. Their role in cardiovascular disease. Circulation 87, 7–13.
Saye, J. A., Ragsdale, N. V., Carey, R. M., and Peach, M. J. (1993) Localization of angiotensinogen peptide-forming enzymes of 3T3-F442A adipocytes. Am. J. Physiol. 264, C1570–C1576.
Crandall, D. L., Herzlinger, H. E., Saunders, B. D., and Kral, J. G. (1994) Development aspects of the adipose tissue renin-angiotensin system: therapeutic implications. Drug Dev. Res. 32, 117–125.
Harp, J. B. and DiGirolamo, M. (1995) Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J. Gerontol. Biol. Sci. Med. Sci. 50, B270–B276.
Schling, P., Mallow, H., Trindl, A., and Löffler, G. (1999) Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int. J. Obes. 23, 336–341.
Rocchini, A. P. (1991) Insulin resistance and blood pressure regulation in obese and nonobese subjects. Hypertension 17, 837–842.
Darimont, C., Vassaux, G., Ailhaud, G., and Négrel, R. (1994) Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin II. Endocrinology 135, 2030–2036.
Zorad, S., Fickova, M., Zelezna, B., Macho, J., and Kral, J. G. (1995) The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen. Physiol. Biophys. 14, 383–391.
Jones, B. H., Standridge, M. K., and Moustaid, N. (1997) Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 138, 1512–1519.
Van Meijer, M. and Pannekoek, H. (1995) Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 9, 263–276.
Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H. G., and Marotti, K. R. (1990) Development of venous occlusions in mice transgenic for the PAI-1 gene. Nature 346, 74–76.
Carmeliet, P., Stassen, J. M., Schoonjans, L., Ream, B., Van den Oord, J. J., De Mol, M., Mulligan, R. C., and Collen, D. (1993) Plasminogen activator inhibitor 1 gene deficient mice. II. Effects on hemostasis thrombosis and thrombolysis. J. Clin. Invest. 92, 2756–2760.
Hamsten, A., De Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blombäck, M., and Wiman, B. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet II, 3.
Juhan-Vague, I., Pyke, S., Alessi, M. C., and Thompsom, S. (1996) Fibrinolytic factor and the risk of myocardial infarction of sudden death in patients with angina pectoris: results of ECAT study. Circulation 94, 2057–2063.
Juhan-Vague, I., Alessi, M. C., and Morange, P. (1999) Obesity and insulin resistance, in Contemporary Endocrinology Insulin Resistance (Reaven, G. and Laws, A., eds.), Humana Press Inc., Totowa, NJ, pp. 317–332.
Samad, F., Yamamoto, K., Pandey, M., and Loskutoff, D. (1997) Elevated expression of transforming growth factor-b in adipose tissue from obese mice. Mol. Med. 3, 36–47.
Morange, P. E., Aubert, J., Peiretti, F., Lijnen, H. R., Vague, P., Verdier, M., Negrel, R., Juhan-Vague, I., and Alessi, M. C. (1999) Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 48, 890–895.
Shimomura, I., Funahashi, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemujra, K., Tokunaga, K., and Matsuzawa, Y. (1996) Enhanced expression of PAI-1 in visceral fat possible contributor to vascular disease in obesity. Nat. Med. 2, 800–803.
Eriksson, P., Reynisdottir, S., Lönnqvist, F., Stemme, V., and Arner, P. (1998) Adipose tissue secretiion of plasminogen activator inhibitor-1 in non obese individuals. Diabetologia 41, 65–71.
Lundgren, C. H., Brown, S. L., Nordt, T. K., Sobel, B. E., and Fujii, S. (1996) Elaboration of type 1 Plasminogen Activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 93, 106–110.
Richelsen, B. (1991) Prostaglandins in adipose tissue. Danish Med. Bull. 38, 228–244.
Vassaux, G., Gaillard, D., Darimont, C., Ailhaud, G., and Négrel, R. (1992) Differential response of preadipocytes and adipocytes to PGI2 and PGE2: physiological implications. Endocrinology 131, 2393–2398.
Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M. Sugimoto, Y., and Narumiya, S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chines hamster ovary cells. Br. J. Pharmacol. 122, 217–224.
Börglum, J. D., Pedersen, S. B., Ailhaud, G., Négrel, R., and Richelsen, B. (1999) Differential expression of prostaglandin receptor mRNAs during adipose cell differentiation. Prostaglandins Other Lipid Mediators 57, 305–317.
Weksler, B. B., Marcus, A. J., and Jaffe, E. A. (1977) Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc. Natl. Acad. Sci. USA 74, 3922–3926.
Négrel, R. and Ailhaud, G. (1981) Metabolism of arachidonic acid and prostaglandin synthesis in the preadipocyte clonal line Ob 17. Biochem. Biophys. Res. Commun. 98, 768–777.
Hyman, B. T., Stoll, L. L., and Spector, A. A. (1982) Prostaglandin production by 3T3-L1 cells in culture. Biochim. Biophys. Acta 713, 375–385.
Axelrod, L., Minnich, A. K., and Ryan, C. A. (1985) Stimulation of prostacyclin production in isolated rat adipocytes by angiotensin II, vasopressin and bradikinin: evidence for two separate mechanisms of prostaglandin synthesis. Endocrinology 116, 2548–2553.
Négrel, R. (1999) Prostacyclin as a critical prostanoid in adipogenesis. Prostaglandins Leukotrienes Essential Fatty Acids 60, 383–386.
Gaillard, D., Négrel, R., Lagarde, M., and Ailhaud, G. (1989) Requirement and role of arachidonic acid in the differentiation of preadipose cells. Biochem. J. 257, 389–397.
Négrel, R., Gaillard, G., and Ailhaud, G. (1989) Prostacyclin as a potent effector of adipose cell differentiation. Biochem. J. 257, 399–405.
Vassaux, G., Gaillard, D., Ailhaud, G., and Négrel, R. (1992) prostacyclin is a specific effector of adipose cell differentiation: its dual role as a cAMP-and Calcium-elevating agent. J. Biol. Chem. 267, 11,092–11,097.
Catalioto, R. M., Gaillard, D., Maclouf, J. Ailhaud, G., and Négrel, R. (1991) Autocrine control of adipose cell differentiation by prostacyclin and PGF2α. Biochim. Biophys. Acta 1091, 364–369.
Aubert, J., Ailhaud, G., and Négrel, R. (1996) Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Lett. 397, 117–121.
Forman, B. M., Chen, J., and Evans, R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptor. Proc. Natl. Acad. Sci. USA 94, 4312–4317.
Bastié, C., Holts, D., Gaillard, D. Jehl-Pietri, C., and Grimaldi, P. A. (1999) Expression of peroxisome proliferator-activated receptor PPARd promotes induction of PPARg and adipocyte differentiation in 3T3C2 fibroblasts. J. Biol. Chem. 274, 21,920–21,925.
Brun, R. P., Tontonoz, P., Forman, B. M., Ellis, R., Chen, J., Evans, R. M., and Spiegelman, B. M. (1996) Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10, 974–984.
Jacobsen, J. and Poulsen, K. (1985) Characterization of angiotensin I, II and III from mouse as position-5 isoleucine angiotensins? An HPLC study. J. Hypertension 3, 155–157.
Declerck, P. J., Moreau, H., Jespersen, J., Gram, J., and Kluft, C. (1993) Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor 1 (PAI-1) Thromb. Haemost. 70, 858–863.
Kates, M., ed. (1986) Laboratory Techniques in Biochemistry and Molecular Biology. Techniques in Lipidology: Isolation, Analysis and Identification of Lipids. Elsevier, Amsterdam.
Sealey, J. E. and Laragh, J. H. (1975) Radioimmunoassay of plasma renin activity. Semin. Nucl. Med. 5, 189–202.
Aubert, J., Darimont, C., Safonova, I., Ailhaud, G., and Négrel, R. (1997) Regulation by glucocorticoids of angiotensin gene expression and secretion in adipose cells. Biochem. J. 328, 701–706.
Juhan-Vague, I., Alessi, M. C., Raccah, D., Aillaud, M. F, Billerey M., Ansaldi J., Philip-Joet C., and Vague P. (1992) Daytime fluctuation of plasminogen activator inhibitor-1 (PAI-1) in populations with high PAI-1 levels. Thromb. Haemost., 67, 76–82.
Hendriks, H. F., Veenstra, J., mnVelthuis-te Xierik, E. J. M., Schaafsma, G., and Kluft, C. (1994) Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br. Med. J. 308, 1003–1006.
Kluft, C. and Verheijen, J. H. (1990) Leiden fibrinolysis working party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) Fibrinolysis 4, 155–160.
Booth, N. A., Simpson, A. J., Croll, A., Bennett, B., and mnMac Gregor, I. R. (1988) Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br. J. Haematol. 70, 327–333.
Sidelmann, J. (1994) The influence of centrifugation load on platelet number and PAI-1 antigen concentration in human plasma. Fibrinolysis 8, 148–150.
Kooistra, T., Sprengers, E. D., and van Hinsbergh, V. W. M. (1986) Rapid inactivation of plasminogen activator inhibitor upon secretion from cultured human endothelial cells. Biochem. J. 239, 497–503.
Sawdey, M. and Loskutoff, D. J. (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-a, and transforming growth factor-b. J. Clin. Invest. 88, 1346–1353.
Declerck, P. J., Verstreken, M., and Collen, D. (1995) Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb. Haemost. 74, 1305–1309.
Ngo, T. H., Verheyen, S., Knockaert, I., and Declerck, P. J. (1998) Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb. Haemost. 79, 808–812.
Granelli-Piperno, A. and Reich, E. (1978) A study of proteases and protease-inhibitor complexes in biological fluids. J. Exp. Med. 148, 223–234.
Hauert, J., Nicoloso, G., Schleuning, W. D., Bachmann F., and Schapira, M. (1989) Plasminogen activators in dextran-sulfate activated euglobulin fractions: a molecular analysis of factor XII and prekallikrein dependent fibrinolysis. Blood 73, 994–999.
Erickson, L. A., Lawrence, D. A., and Loskutoff, D. J. (1984) Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate polyacrylamide gel electrophoresis. Anal. Biochem. 137, 454–463.
Cajot, J. F., Kruithof, E. K. O., Schleuning, W. D., Sordat, B., and Bachmann, F. (1986) Plasminogen activator, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int. J. Cancer. 38, 719–727.
Laemlli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.
Gaillard, D., Wabitsch, M., Pipy, B., and Négrel, R. (1991) Control of terminal differentiation of adipose precursor cells by glucocorticoids. J. Lipid Res. 32, 569–579.
Darimont, C., Vassaux, G., Gaillard, D., Ailhaud, G., and Négrel, R. (1994) In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int. J. Obes. 18, 783–788.
Bligh, E. G. and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911–917.
Powell, W. S. (1982) Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol. 86, 467–477.
N#x00E9;grel, R., Grimaldi, P., and Ailhaud, G. (1981) Differentiation of Ob17 preadipocytes to adipocytes. Effects of prostaglandinF2a and relationship to prostaglandin synthesis. Biochim. Biophys. Acta. 666, 15–24.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Alessi, MC., Aubert, J., Négrel, R. (2001). Measurements of Peptide and Nonpeptide Secretory Products from Adipocytes. In: Ailhaud, G. (eds) Adipose Tissue Protocols. Methods in Molecular Biology™, vol 155. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-231-7:249
Download citation
DOI: https://doi.org/10.1385/1-59259-231-7:249
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-747-2
Online ISBN: 978-1-59259-231-9
eBook Packages: Springer Protocols